How have recent PCSK9 trials affected your position on the role of intensifying LDL-C reductions to new target levels, and how are they likely to affect future global/ESC 2019 guidelines for LDL-mediated CV risk reduction?

How have recent PCSK9 trials affected your position on the role of intensifying LDL-C reductions to new target levels, and how are they likely to affect future global/ESC 2019 guidelines for LDL-mediated CV risk reduction?

How have recent PCSK9 trials affected your position on the role of intensifying LDL-C reductions to new target levels, and how are they likely to affect future global/ESC 2019 guidelines for LDL-mediated CV risk reduction?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Alberico Catapano, PhD

Alberico Catapano, PhD

Full Professor of Pharmacology University of Milano Director, Laboratory for the Study of Lipoproteins and Atherosclerosis Director, Center for the Study of Atherosclerosis of the Italian Society of Atherosclerosis